Pharmaceutical Research 2003-10-01

The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction.

Hiromi Okabe, Miyako Hasunuma, Yukiya Hashimoto

Index: Pharm. Res. 20(10) , 1591-4, (2003)

Full Text: HTML

Abstract

The hepatic and intestinal metabolic activities of P450 were evaluated in rats with surgery- and drug-induced renal dysfunction.Renal failure was induced by five-sixths nephrectomy (NR), bilateral ureter ligation (BUL), the intramuscular injection of glycerol (GL), and the intraperitoneal injection of cisplatin (CDDP). Phenytoin 4-hydroxylation, debrisoquine 4-hydroxylation, and testosterone 6beta-hydroxylation were estimated to evaluate the metabolic activities of cytochrome P450 (CYP) 2C, 2D, and 3A, respectively.The hepatic CYP3A metabolic activities were decreased by 65.9% and 60.2% in NR and GL rats, respectively. The hepatic CYP2C metabolic activity was decreased by 48.8% in CDDP rats. No alteration in hepatic drug-metabolizing activities was observed in BUL rats. On the other hand, the intestinal CYP3A metabolic activity was weakly increased in GL rats but not significantly altered in NR, CDDP, and BUL rats.This study suggested (a) that only selected P450 metabolic activity in the liver is decreased in renal failure, (b) that extent of the decrease in hepatic metabolic activities of P450 is dependent on the etiology of renal failure, and (c) that alteration of CYP3A metabolic activity in the intestine is not always correlated with that in the liver.


Related Compounds

Related Articles:

Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate.

1999-08-01

[Biochem. Pharmacol. 58(3) , 439-45, (1999)]

Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

1998-03-01

[Br. J. Clin. Pharmacol. 45(3) , 315-7, (1998)]

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.

2005-01-01

[Clin. Chem. Lab Med. 43(3) , 275-9, (2005)]

Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.

1999-01-01

[Chirality 11(7) , 591-7, (1999)]

Debrisoquine hydroxylation in Parkinson's disease.

1992-08-01

[Acta Neurol. Scand 86(2) , 159-64, (1992)]

More Articles...